Skip to content

About Us

Epistem At A Glance

Epistem prides itself on its commitment to providing reliable, innovative, and transferable models and services to support decision making throughout the drug discovery, development, and early clinical pipeline.

Vision Statement: To innovate unique solutions to biomedical challenges through defining expertise.

Our Mission

To accelerate therapies to market by providing innovative and dependable solutions to complex biomedical challenges.

Our History

Founded in 2000, followed by a management buy-out in 2018, Epistem continues to thrive as a privately owned company, with over 200 pharmaceutical and biotechnology companies working with us.

Our Team

With a wealth of experience in taking novel therapeutic agents from early-stage in vitro testing to clinical candidate nomination and clinical trial support, Epistem's technical team is well-equipped to assist and advise on appropriate models and custom protocols in accordance with study objectives.

Our Future

Epistem continues to develop innovative and clinically relevant assays and models to support the drug discovery and development pipeline. In addition to in-house development, Epistem also collaborates with commercial and academic partners to develop and validate novel, state-of-the-art models.

Who We Are

At Epistem, we are proud to offer specialist research services that provide invaluable support to drug discovery and development pipelines.

Our preclinical services encompass both in vitro and in vivo, with a focus on oncology and inflammatory diseases, as well as extensive experience in the gastrointestinal disease area, including GI toxicities. Our GCLP accredited laboratories provide support for histology, IHC, and image analysis, as well as gene expression and DNA genotyping services.

Our experienced and highly skilled technical team is dedicated to delivering custom protocols and personalised services of the utmost quality, tailored specifically to meet your needs. With a track record of working with over 200 pharmaceutical and biotechnology companies, we offer preclinical and clinical services that you can count on.

We operate under both contractual fee-for-service models, as well as collaborative partnerships, particularly in model development and biomarker and target discovery programs. Our customer focus and high level of expertise have earned us an enviable track record and an impressive ratio of repeat business.

At Epistem, we are committed to delivering the highest quality services and support to our clients, every step of the way.

Our Team

We have a diverse group of individuals who bring their unique perspectives and experiences to the table, and we believe that this diversity is one of our greatest strengths. Our team is comprised of experts in their respective fields who work tirelessly to deliver exceptional results to our clients. We are passionate about what we do and take great pride in the work we produce. Our goal is to not only meet but exceed our clients' expectations, and we believe that our team is more than capable of doing just that. So take a moment to get to know us, and we look forward to working with you.

Dr Cath Booth

Chief Executive Officer

Julie Tudor

Operations Director

Andrew Edwards

Commercial Director

James Fullerton-Batten

Chief Financial Officer

Dr Nick Ash

Non-Executive Chairman

Matthew Pomroy

Non-Executive Director

Aude-Marine Bonavita

Senior Business Development Manager

Dr Juan B Menendez Gonzalez

Business Development Manager

Faye Mansfield

Marketing Officer

Oliver Hill

Account Development Manager Inside Sales & Marketing Assistant

Dr James Wilson

Principal Scientist

Dr Alan Murdoch

Senior Scientist

Dr James McConnell

Senior Scientist

Dr Frida Ponthan

Senior Scientist

Dr Fernando Magdaleno Verduzco

Senior Scientist

Timothy Mefo

Senior Scientist

Dr Valentina Ubertini

Senior Scientist

Adam Boanas

Histology Manager

Dr Gary Beale

Bioinformatician

What We Do

What we do

Epistem specialises in providing innovative solutions to complex problems. Our team of experts are dedicated to developing and implementing cutting-edge research models and analytical platforms to uncover insights that drive positive change. We offer a range of services, in areas from organoid screening platforms through to clinical biomarkers.

We pride ourselves on our commitment to excellence and our ability to tackle complex challenges in the biotech industry. Whether it is conducting research studies or analysing complex data sets, we have the expertise to help our clients achieve their goals. At Epistem, we are committed to supporting our clients and driving advancements in the field of biotechnology.

Epistem strives to meet and exceed customer expectations, and applicable regulatory requirements standards and guidelines. Our Quality Management System applies companywide and is designed to reflect industry best practices for clinical and non-clinical studies.

The Histology, Immunohistochemistry (and associated Image Analysis) and Pharmacogenomics laboratories are accredited to Good Clinical Laboratory Practice and also operate in accordance with:
- ICH GCP
-Clinical Trials Regulation EU No 536/2014 of the European Parliament and of the Council or 16th April 2014 on Clinical Trials on Medicinal Products for Human use, and repealing Directive 2001/20/EC
- EMA Reflection Paper for Laboratories that Perform the Analysis or Evaluation of Clinical Trial Samples

The compliance of our operations with the GCLP guidelines has been repeatedly assessed and confirmed by an independent company, Qualogy Ltd, since 2010, in addition to regular Sponsor audits.

Our GCLP certificate is available to view in Downloads.